[1]
|
Porter, D.L., et al. (2016) Chimeric Antigen Receptor T Cells Persist and Induce Sustained Remissions in Relapsed Refractory Chronic Lymphocytic Leukemia. Science Translational Medicine, 7, 303ra139.
https://doi.org/10.1126/scitranslmed.aac5415
|
[2]
|
Zmievskaya, E., Valiullina, A., Ganeeva, I., Petukhov, A., Rizvanov, A. and Bulatov, E. (2021) Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections. Biomedicines, 9, Article No. 59.
https://doi.org/10.3390/biomedicines9010059
|
[3]
|
Sharpe, M. and Mount, N. (2015) Genetically Modified T Cells in Cancer Therapy: Opportunities and Challenges. Disease Models and Mechanisms, 8, 337-350.
https://doi.org/10.1242/dmm.018036
|
[4]
|
McGuirk, J., et al. (2017) Building Blocks for Institutional Preparation of CTL019 Delivery. Cytotherapy, 19, 1015-1024. https://doi.org/10.1016/j.jcyt.2017.06.001
|
[5]
|
Houot, R., Schultz, L.M., Marabelle, A. and Kohrt, H. (2015) T-Cell-Based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition. Cancer Immunology Research, 3, 1115-1122. https://doi.org/10.1158/2326-6066.CIR-15-0190
|
[6]
|
Barrett, D.M., Grupp, S.A. and June, C.H. (2015) Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street. The Journal of Immunology, 195, 755-761. https://doi.org/10.4049/jimmunol.1500751
|
[7]
|
Verdegaal, E.M.E., et al. (2016) Neoantigen Landscape Dynamics during Human Melanoma-T Cell Interactions. Nature, 536, 91-95.
https://doi.org/10.1038/nature18945
|
[8]
|
Maus, M.V., Grupp, S.A., Porter, D.L. and June, C.H. (2014) Antibody-Modified T Cells: CARs Take the Front Seat for Hematologic Malignancies. Blood, 123, 2625-2635. https://doi.org/10.1182/blood-2013-11-492231
|
[9]
|
Kakarla, S. and Gottschalk, S. (2014) CAR T Cells for Solid Tumors Armed and Ready to Go? https://www.journalppo.com/
|
[10]
|
Gross, G., Waks, T. and Eshhar, Z. (1989) Expression of Immunoglobulin-T-cell Receptor Chimeric Molecules as Functional Receptors with Antibody-Type Specificity. Proceedings of the National Academy of Sciences of the United States of America, 86, 10024-10028. https://doi.org/10.1073/pnas.86.24.10024
|
[11]
|
Enblad, G., Karlsson, H. and Loskog, A.S.I. (2015) CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma. Human Gene Therapy, 26, 498-505. https://doi.org/10.1089/hum.2015.054
|
[12]
|
Tang, H., Qiao, J. and Fu, Y.X. (2016) Immunotherapy and Tumor Microenvironment. Cancer Letters, 370, 85-90. https://doi.org/10.1016/j.canlet.2015.10.009
|
[13]
|
Levine, B.L. (2015) Performance-Enhancing Drugs: Design and Production of Redirected Chimeric Antigen Receptor (CAR) T Cells. Cancer Gene Therapy, 22, 79-84.
https://doi.org/10.1038/cgt.2015.5
|
[14]
|
Maus, M.V. and Levine, B.L. (2016) Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. The Oncologist, 21, 608-617.
https://doi.org/10.1634/theoncologist.2015-0421
|
[15]
|
Tanaka, J., Mielcarek, M. and Torok-Storb, B. (1998) Impaired Induction of the CD28-Responsive Complex in Granulocyte Colony-Stimulating Factor Mobilized CD4 T Cells. Blood, 91, 347-352. https://doi.org/10.1182/blood.V91.1.347
|
[16]
|
Shank, B.R., Do, B., Sevin, A., Chen, S.E., Neelapu, S.S. and Horowitz, S.B. (2017) Chimeric Antigen Receptor T Cells in Hematologic Malignancies. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 37, Article ID: 334345. https://doi.org/10.1002/phar.1900
|
[17]
|
Vormittag, P., Gunn, R., Ghorashian, S. and Veraitch, F.S. (2018) A Guide to Manufacturing CAR T Cell Therapies. Current Opinion in Biotechnology, 53, 164-181.
https://doi.org/10.1016/j.copbio.2018.01.025
|
[18]
|
Eshhar, Z., Waks, T., Gross, G. and Schindler, D.G. (1993) Specific Activation and Targeting of Cytotoxic Lymphocytes through Chimeric Single Chains Consisting of Antibody-Binding Domains and the γ or ζ Subunits of the Immunoglobulin and T-Cell Receptors. Proceedings of the National Academy of Sciences of the United States of America, 90, 720-724. https://doi.org/10.1073/pnas.90.2.720
|
[19]
|
Maher, J. (2012) Immunotherapy of Malignant Disease Using Chimeric Antigen Receptor Engrafted T Cells. International Scholarly Research Notices, 2012, Article ID: 278093. https://doi.org/10.5402/2012/278093
|
[20]
|
Stone J.D. and Kranz, D.M. (2013) Role of T Cell Receptor Affinity in the Efficacy and Specificity of Adoptive T Cell Therapies. Frontiers in Immunology, 4, Article No. 244. https://doi.org/10.3389/fimmu.2013.00244
|
[21]
|
Kershaw, M. H., et al. (2006) A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer. Clinical Cancer Research, 12, 6106-6115.
|
[22]
|
Rodriguez-Cartagena, L.G., Bowles, B.S., Kurani, S.S., Windebank, A.J., Kenderian, S.S. and Greenberg-Worisek, A.J. (2018) Chimeric Antigen Receptor T-Cells: Successful Translation of the First Cell and Gene Therapy from Bench to Bedside. Clinical and Translational Science, 11, 537-539. https://doi.org/10.1111/cts.12586
|
[23]
|
Smith, A.J., Oertle, J., Warren, D. and Prato, D. (2016) Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Cancers: Summary and Perspective. Journal of Cellular Immunotherapy, 2, 59-68. https://doi.org/10.1016/j.jocit.2016.08.001
|
[24]
|
Bird, R.E., Hardman, K.D., Jacobson, J.W., Johnson, S., Kaufman, B., et al. (1988) Single-Chain Antigen-Binding Proteins. Science, 242, 423-426.
https://doi.org/10.1126/science.3140379
|
[25]
|
Chen, X., Zaro, J.L. and Shen, W.C. (2013) Fusion Protein Linkers: Property, Design and Functionality. Advanced Drug Delivery Reviews, 65, 1357-1369.
https://doi.org/10.1016/j.addr.2012.09.039
|
[26]
|
Ward, D.E., Fay, B.L., Adejuwon, A., Han, H. and Ma, Z. (2018) Chimeric Antigen Receptors Based on Low Affinity Mutants of FcεRI Re-Direct T Cell Specificity to Cells Expressing Membrane IgE. Frontiers in Immunology, 9, Article No. 2231.
https://doi.org/10.3389/fimmu.2018.02231
|
[27]
|
Hudecek, M., et al. (2015) The NonSignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for in Vivo Antitumor Activity. Cancer Immunology Research, 3, 125-135. https://doi.org/10.1158/2326-6066.CIR-14-0127
|
[28]
|
Hombach, A.A., Schildgen, V., Heuser, C., Finnern, R., Gilham, D.E. and Abken, H. (2007) T Cell Activation by Antibody-Like Immunoreceptors: The Position of the Binding Epitope within the Target Molecule Determines the Efficiency of Activation of Redirected T Cells. The Journal of Immunology, 178, 4650-4657.
https://doi.org/10.4049/jimmunol.178.7.4650
|
[29]
|
Zhang, T., Wu, M.-R. and Sentman, C.L. (2012) An NKp30-Based Chimeric Antigen Receptor Promotes T Cell Effector Functions and Antitumor Efficacy In Vivo. The Journal of Immunology, 189, 2290-2299.
https://doi.org/10.4049/jimmunol.1103495
|
[30]
|
Guedan, S., et al. (2018) Enhancing CAR T Cell Persistence through ICOS and 4-1BB Costimulation. JCI Insight, 3, e96976.
https://doi.org/10.1172/jci.insight.96976
|
[31]
|
Zabel, M., Tauber, P.A. and Pickl, W.F. (2019) The Making and Function of CAR Cells. Immunology Letters, 212, 53-69. https://doi.org/10.1016/j.imlet.2019.06.002
|
[32]
|
Smith, J.W. (1997) Apheresis Techniques and Cellular Immunomodulation. Therapeutic Apheresis, 1, 20-206. https://doi.org/10.1111/j.1744-9987.1997.tb00137.x
|
[33]
|
Suhoski, M.M., et al. (2007) Engineering Artificial Antigen-Presenting Cells to Express a Diverse Array of Co-Stimulatory Molecules. Molecular Therapy, 15, 981-988. https://doi.org/10.1038/mt.sj.6300134
|
[34]
|
Leyfman, Y. (2018) Chimeric Antigen Receptors: Unleashing a New Age of Anti-Cancer Therapy. Cancer Cell International, 18, Article No. 182.
https://doi.org/10.1186/s12935-018-0685-x
|
[35]
|
Seif, M., Einsele, H. and Loffler, J. (2019) CAR T Cells beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases. Frontiers in Immunology, 10, Article No. 2711. https://doi.org/10.3389/fimmu.2019.02711
|
[36]
|
Masiero, S., et al. (2005) T-Cell Engineering by a Chimeric T-Cell Receptor with Antibody-Type Specificity for the HIV-1 gp120. Gene Therapy, 12, 299-310.
https://doi.org/10.1038/sj.gt.3302413
|
[37]
|
Liu, B., Zhang, W. and Zhang, H. (2019) Development of CAR-T Cells for Long-Term Eradication and Surveillance of HIV-1 Reservoir. Current Opinion in Virology, 38, 21-30. https://doi.org/10.1016/j.coviro.2019.04.004
|
[38]
|
Vagnozzi, R.J., Johansen, A.K.Z. and Molkentin, J.D. (2019) CARdiac Immunotherapy: T Cells Engineered to Treat the Fibrotic Heart. Molecular Therapy, 27, 1869-1871. https://doi.org/10.1016/j.ymthe.2019.09.021
|
[39]
|
Aghajanian, H., et al. (2019) Targeting Cardiac Fibrosis with Engineered T Cells. Nature, 573, 430-433. https://doi.org/10.1038/s41586-019-1546-z
|
[40]
|
CAR T Cell immunotherapy—List Results. ClinicalTrials.gov.
https://clinicaltrials.gov/ct2/results?cond=CAR+T+Cell+immunotherapy&term=&cntry=&state=&city=&dist
|
[41]
|
FDA. https://www.fda.gov/search?s=CAR+T+cell+efficacy+rate
|
[42]
|
Zhao, Z., Chen, Y., Francisco, N.M., Zhang, Y. and Wu, M. (2018) The Application of CAR-T Cell Therapy in Hematological Malignancies: Advantages and Challenges. Acta Pharmaceutica Sinica B, 8, 539-551.
https://doi.org/10.1016/j.apsb.2018.03.001
|
[43]
|
Davila, M.L., et al. (2014) Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy. Science Translational Medicine, 6, 224-225.
https://doi.org/10.1126/scitranslmed.3008226
|
[44]
|
Davila, M.L. and Sadelain, M. (2016) Biology and Clinical Application of CAR T Cells for B Cell Malignancies. International Journal of Hematology, 104, 6-17.
https://doi.org/10.1007/s12185-016-2039-6
|
[45]
|
Lee, D.W., et al. (2015) T Cells Expressing CD19 Chimeric Antigen Receptors for Acute Lymphoblastic Leukaemia in Children and Young Adults: A Phase 1 Dose-Escalation Trial. The Lancet, 385, 517-528.
https://doi.org/10.1016/S0140-6736(14)61403-3
|
[46]
|
Shalabi, H., Angiolillo, A. and Fry, T.J. (2015) Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia. Frontiers in Pediatrics, 3, Article No. 80.
https://doi.org/10.3389/fped.2015.00080
|
[47]
|
Maude, S.L., Barrett, D., Teachey, D.T. and Grupp, S.A. (2014) Managing Cytokine Release Syndrome Associated with Novel T Cell-Engaging Therapies. The Cancer Journal, 20, 119-122. https://doi.org/10.1097/PPO.0000000000000035
|
[48]
|
Zah, E., Lin, M.Y., Anne, S.B., Jensen, M.C. and Chen, Y.Y. (2016) T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. Cancer Immunology Research, 4, 498-508.
https://doi.org/10.1158/2326-6066.CIR-15-0231
|
[49]
|
Fraietta, J.A., et al. (2016) Ibrutinib Enhances Chimeric Antigen Receptor T-Cell Engraftment and Efficacy in Leukemia. Blood, 127, 1117-1127.
https://doi.org/10.1182/blood-2015-11-679134
|
[50]
|
Roddie, C. and Peggs, K.S. (2011) Donor Lymphocyte Infusion following Allogeneic Hematopoietic Stem Cell Transplantation. Expert Opinion on Biological Therapy, 11, 473-487. https://doi.org/10.1517/14712598.2011.554811
|
[51]
|
Frey, N.V. and Porter, D.L. (2008) Graft-versus-Host Disease after Donor Leukocyte Infusions: Presentation and Management. Best Practice & Research Clinical Haematology, 21, 205-222. https://doi.org/10.1016/j.beha.2008.02.007
|
[52]
|
Chung, C. (2017) Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 37, 129-143.
https://doi.org/10.1002/phar.1871
|
[53]
|
Zhang, K., Desai, A., Zeng, D., Gong, T., Lu, P. and Wang, M. (2017) Magic Year for Multiple Myeloma Therapeutics: Key Takeaways from the ASH 2015 Annual Meeting. Oncotarget, 8, 10748-10759. https://doi.org/10.18632/oncotarget.13314
|
[54]
|
Garfall, A.L., et al. (2015) Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. The New England Journal of Medicine, 373, 1040-1047.
https://doi.org/10.1056/NEJMoa1504542
|
[55]
|
Hajek, R., Okubote, S.A. and Svachova, H. (2013) Myeloma Stem Cell Concepts, Heterogeneity and Plasticity of Multiple Myeloma. British Journal of Haematology, 163, 551-564. https://doi.org/10.1111/bjh.12563
|
[56]
|
Atanackovic, D., Radhakrishnan, S.V., Bhardwaj, N. and Luetkens, T. (2016) Chimeric Antigen Receptor (CAR) Therapy for Multiple Myeloma. British Journal of Haematology, 172, 685-698. https://doi.org/10.1111/bjh.13889
|
[57]
|
Guo, B., et al. (2016) CD138-Directed Adoptive Immunotherapy of Chimeric Antigen Receptor (CAR)-Modified T Cells for Multiple Myeloma. Journal of Cellular Immunotherapy, 2, 28-35. https://doi.org/10.1016/j.jocit.2014.11.001
|
[58]
|
Duong, C.P.M., Yong, C.S.M., Kershaw, M.H., Slaney, C.Y. and Darcy, P.K. (2015) Cancer Immunotherapy Utilizing Gene-Modified T Cells: From the Bench to the Clinic. Molecular Immunology, 67, 46-57.
https://doi.org/10.1016/j.molimm.2014.12.009
|
[59]
|
Kim, S.T., et al. (2013) Tumor-Infiltrating Lymphocytes, Tumor Characteristics, and Recurrence in Patients with Early Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 36, 224-231.
https://doi.org/10.1097/COC.0b013e3182467d90
|
[60]
|
Kmiecik, J., et al. (2013) Elevated CD3+ and CD8+ Tumor-Infiltrating Immune Cells Correlate with Prolonged Survival in Glioblastoma Patients despite Integrated Immunosuppressive Mechanisms in the Tumor Microenvironment and at the Systemic Level. Journal of Neuroimmunology, 264, 71-83.
https://doi.org/10.1016/j.jneuroim.2013.08.013
|
[61]
|
Van der Burg, S.H. and Palefsky, J.M. (2009) Human Immunodeficiency Virus and Human Papilloma Virus—Why HPV-Induced Lesions Do Not Spontaneously Resolve and Why Therapeutic Vaccination Can Be Successful. Journal of Translational Medicine, 7, Article No. 108. https://doi.org/10.1186/1479-5876-7-108
|
[62]
|
Slaney, C.Y., Kershaw, M.H. and Darcy, P.K. (2014) Trafficking of T Cells into Tumors. Cancer Research, 74, 7168-7174.
https://doi.org/10.1158/0008-5472.CAN-14-2458
|
[63]
|
Kershaw, M.H., et al. (2002) Redirecting Migration of T Cells to Chemokine Secreted from Tumors by Genetic Modification with CXCR2. Human Gene Therapy, 13, 1971-1980. https://doi.org/10.1089/10430340260355374
|
[64]
|
Caruana, I., et al. (2015) Heparanase Promotes Tumor Infiltration and Antitumor Activity of CAR-Redirected T Lymphocytes. Nature Medicine, 21, 524-529.
https://doi.org/10.1038/nm.3833
|
[65]
|
Caulier, B., Enserink, J.M. and Walchli, S. (2021) Pharmacologic Control of CAR T Cells. International Journal of Molecular Sciences, 22, Article No. 4320.
https://doi.org/10.3390/ijms22094320
|
[66]
|
Jan, M., et al. (2021) Reversible ON- and OFF-Switch Chimeric Antigen Receptors Controlled by Lenalidomide. Science Translational Medicine, 13, eabb6295.
https://doi.org/10.1126/scitranslmed.abb6295
|
[67]
|
Richman, S.A., Wang, L.C., Moon, E.K., Khire, U.R., Albelda, S.M. and Milone, M.C. (2020) Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity in Vitro and in Vivo. Molecular Therapy, 28, 1600-1613. https://doi.org/10.1016/j.ymthe.2020.06.004
|
[68]
|
Lee, S.M., et al. (2020) A Chemical Switch System to Modulate Chimeric Antigen Receptor T Cell Activity through Proteolysis-Targeting Chimaera Technology. ACS Synthetic Biology, 9, 987-992. https://doi.org/10.1021/acssynbio.9b00476
|
[69]
|
Giordano-Attianese, G., et al. (2020) A Computationally Designed Chimeric Antigen Receptor Provides a Small-Molecule Safety Switch for T-Cell Therapy. Nature Biotechnology, 38, 426-432. https://doi.org/10.1038/s41587-019-0403-9
|
[70]
|
Zajc, C.U., et al. (2020) A Conformation-Specific ON-Switch for Controlling CAR T Cells with an Orally Available Drug. Proceedings of the National Academy of Sciences of the United States of America, 117, 14926-14935.
https://doi.org/10.1073/pnas.1911154117
|
[71]
|
Juillerat, A., et al. (2019) Modulation of Chimeric Antigen Receptor Surface Expression by a Small Molecule Switch. BMC Biotechnology, 19, Article No. 44.
https://doi.org/10.1186/s12896-019-0537-3
|
[72]
|
Weber, E.W., Lynn, R.C., Sotillo, E., Lattin, J., Xu, P. and Mackall, C.L. (2019) Pharmacologic Control of CAR-T Cell Function Using Dasatinib. Blood Advances, 3, 711-717. https://doi.org/10.1182/bloodadvances.2018028720
|
[73]
|
Mestermann, K., et al. (2019) The Tyrosine Kinase Inhibitor Dasatinib Acts as a Pharmacologic on/off Switch for CAR T Cells. Science Translational Medicine, 11, eaau5907. https://doi.org/10.1126/scitranslmed.aau5907
|
[74]
|
Hill, Z.B., Martinko, A.J., Nguyen, D.P. and Wells, J.A. (2018) Human Antibody-Based Chemically Induced Dimerizers for Cell Therapeutic Applications. Nature Chemical Biology, 14, 112-117. https://doi.org/10.1038/nchembio.2529
|
[75]
|
Foster, A.E., et al. (2017) Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40. Molecular Therapy, 25, 2176-2188.
https://doi.org/10.1016/j.ymthe.2017.06.014
|
[76]
|
Wu, C.Y., Roybal, K.T., Puchner, E.M., Onuffer, J. and Lim, W.A. (2015) Remote Control of Therapeutic T Cells through a Small Molecule-Gated Chimeric Receptor. Science, 350, aab4077. https://doi.org/10.1126/science.aab4077
|
[77]
|
Park, S., et al. (2021) Direct Control of CAR T Cells through Small Molecule-Regulated Antibodies. Nature Communications, 12, Article No. 710.
https://doi.org/10.1038/s41467-020-20671-6
|
[78]
|
Cho, J.H., Collins, J.J. and Wong, W.W. (2018) Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses. Cell, 173, 1426-1438.
https://doi.org/10.1016/j.cell.2018.03.038
|
[79]
|
Cartellieri, M., et al. (2016) Switching CAR T Cells on and off: A Novel Modular Platform for Retargeting of T Cells to AML Blasts. Blood Cancer Journal, 6, e458.
https://doi.org/10.1038/bcj.2016.61
|
[80]
|
Ma, J.S.Y., et al. (2016) Versatile Strategy for Controlling the Specificity and Activity of Engineered T Cells. Proceedings of the National Academy of Sciences of the United States of America, 113, E450-E458. https://doi.org/10.1073/pnas.1524193113
|
[81]
|
Dufva, O., et al. (2020) Integrated Drug Profiling and CRISPR Screening Identify Essential Pathways for CAR T-Cell Cytotoxicity. Blood, 135, 597-609.
https://doi.org/10.1182/blood.2019002121
http://ashpublications.org/blood/article-pdf/135/9/597/1717506/bloodbld2019002121.pdf
|
[82]
|
Li, H., et al. (2019) CAIX-Specific CAR-T Cells and Sunitinib Show Synergistic Effects against Metastatic Renal Cancer Models. Journal of Immunotherapy, 43, 16-28. https://doi.org/10.1097/CJI.0000000000000301
https://www.immunotherapy-journal.com/
|
[83]
|
Torres-Collado, A.X. and Jazirehi, A.R. (2018) Overcoming Resistance of Human Non-Hodgkin’s Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors. Cancers, 10, Article No. 200.
https://doi.org/10.3390/cancers10060200
|
[84]
|
Jetani, H., et al. (2018) CAR T-Cells Targeting FLT3 Have Potent Activity against FLT3−ITD+ AML and Act Synergistically with the FLT3-Inhibitor Crenolanib. Leukemia, 32, 1168-1179. https://doi.org/10.1038/s41375-018-0009-0
|
[85]
|
Urak, R., et al. (2017) Ex Vivo Akt Inhibition Promotes the Generation of Potent CD19CAR T Cells for Adoptive Immunotherapy. Journal for ImmunoTherapy of Cancer, 5, Article No. 26. https://doi.org/10.1186/s40425-017-0227-4
|
[86]
|
John, L.B., et al. (2013) Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors by Gene-Modified T Cells. Clinical Cancer Research, 19, 5636-5646. https://doi.org/10.1158/1078-0432.CCR-13-0458
|
[87]
|
Karlsson, S.C.H., et al. (2013) Combining CAR T Cells and the Bcl-2 Family Apoptosis Inhibitor ABT-737 for Treating B-Cell Malignancy. Cancer Gene Therapy, 20, 386-393. https://doi.org/10.1038/cgt.2013.35
|
[88]
|
Sterner, R.M., et al. (2019) GM-CSF Inhibition Reduces Cytokine Release Syndrome and Neuroinflammation but Enhances CAR-T Cell Function in Xenografts. Blood, 133, 697-709. https://doi.org/10.1182/blood-2018-10-881722
http://ashpublications.org/blood/article-pdf/133/7/697/1552534/blood881722.pdf
|
[89]
|
Pennell, C.A., et al. (2018) Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. Molecular Therapy, 26, 1423-1434. https://doi.org/10.1016/j.ymthe.2018.04.006
|
[90]
|
Norelli, M., et al. (2018) Monocyte-Derived IL-1 and IL-6 Are Differentially Required for Cytokine-Release Syndrome and Neurotoxicity Due to CAR T Cells. Nature Medicine, 24, 739-748. https://doi.org/10.1038/s41591-018-0036-4
|
[91]
|
Giavridis, T., van der Stegen, S.J.C., Eyquem, J., Hamieh, M., Piersigilli, A. and Sadelain, M. (2018) CAR T Cell-Induced Cytokine Release Syndrome Is Mediated by Macrophages and Abated by IL-1 Blockade. Nature Medicine, 24, 731-738.
https://doi.org/10.1038/s41591-018-0041-7
|
[92]
|
Staedtke, V., et al. (2018) Disruption of a Self-Amplifying Catecholamine Loop Reduces Cytokine Release Syndrome. Nature, 564, 273-277.
https://doi.org/10.1038/s41586-018-0774-y
|
[93]
|
Turtle, C.J., et al. (2016) CD19 CAR-T Cells of Defined CD4+:CD8+ Composition in Adult B Cell ALL Patients. Journal of Clinical Investigation, 126, 2123-2138.
https://doi.org/10.1172/JCI85309
|
[94]
|
Stavrou, M., et al. (2018) A Rapamycin-Activated Caspase 9-Based Suicide Gene. Molecular Therapy, 26, 1266-1276. https://doi.org/10.1016/j.ymthe.2018.03.001
|
[95]
|
Diaconu, I., et al. (2017) Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells. Molecular Therapy, 25, 580-592. https://doi.org/10.1016/j.ymthe.2017.01.011
|
[96]
|
Philip, B., et al. (2014) A Highly Compact Epitope-Based Marker/Suicide Gene for Easier and Safer T-Cell Therapy. Blood, 124, 1277-1287.
https://doi.org/10.1182/blood-2014-01-545020
|
[97]
|
Grupp, S.A., et al. (2013) Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia. The New England Journal of Medicine, 368, 1509-1518.
https://doi.org/10.1056/NEJMoa1215134
|
[98]
|
Kochenderfer, J.N., et al. (2012) B-Cell Depletion and Remissions of Malignancy Along with Cytokine-Associated Toxicity in a Clinical Trial of Anti-CD19 Chimeric-Antigen-Receptor-Transduced T Cells. Blood, 119, 2709-2720.
https://doi.org/10.1182/blood-2011-10-384388
|
[99]
|
Kochenderfer, J.N., et al. (2010) Eradication of B-Lineage Cells and Regression of Lymphoma in a Patient Treated with Autologous T Cells Genetically Engineered to Recognize CD19. Blood, 116, 4099-4102.
https://doi.org/10.1182/blood-2010-04-281931
|
[100]
|
Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M. and Rosenberg, S.A. (2010) Case Report of a Serious Adverse Event following the Administration of T Cells Transduced with a Chimeric Antigen Receptor Recognizing ERBB2. Molecular Therapy, 18, 843-851. https://doi.org/10.1038/mt.2010.24
|
[101]
|
Cameron, B.J., et al. (2013) Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells. Science Translational Medicine, 5, 197ra103.
https://doi.org/10.1126/scitranslmed.3006034
|
[102]
|
Porter, D.L., Levine, B.L., Kalos, M., Bagg, A. and June, C.H. (2011) Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia. The New England Journal of Medicine, 365, 725-733. https://doi.org/10.1056/NEJMoa1103849
|
[103]
|
Brentjens, R.J., et al. (2011) Safety and Persistence of Adoptively Transferred Autologous CD19-Targeted T Cells in Patients with Relapsed or Chemotherapy Refractory B-Cell Leukemias. Blood, 118, 4817-4828.
https://doi.org/10.1182/blood-2011-04-348540
|
[104]
|
Kochenderfer, J.N., et al. (2013) Donor-Derived CD19-Targeted T Cells Cause Regression of Malignancy Persisting after Allogeneic Hematopoietic Stem Cell Transplantation Key Points. Blood, 122, Article No. 151.
https://doi.org/10.1182/blood.V122.21.151.151
|
[105]
|
Maus, M.V., et al. (2013) T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans. Cancer Immunology Research, 1, 26-31.
https://doi.org/10.1158/2326-6066.CIR-13-0006
|
[106]
|
Brentjens, R.J., et al. (2013) CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Science Translational Medicine, 5, 177ra38.
https://doi.org/10.1126/scitranslmed.3005930
|
[107]
|
Maude, S.L., et al. (2014) Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. The New England Journal of Medicine, 371, 1507-1517.
https://doi.org/10.1056/NEJMoa1407222
|
[108]
|
Barrett, D.M., Teachey, D.T. and Grupp, S.A. (2014) Toxicity Management for Patients Receiving Novel T-Cell Engaging Therapies. Current Opinion in Pediatrics, 26, 43-49. https://doi.org/10.1097/MOP.0000000000000043
|
[109]
|
Maus, M.V. and June, C.H. (2016) Making Better Chimeric Antigen Receptors for Adoptive T-Cell Therapy. Clinical Cancer Research, 22, 1875-1884.
https://doi.org/10.1158/1078-0432.CCR-15-1433
|
[110]
|
Kalaitsidou, M., Kueberuwa, G., Schütt, A. and Gilham, D.E. (2015) CAR T-Cell Therapy: Toxicity and the Relevance of Preclinical Models. Immunotherapy, 7, 487-497. https://doi.org/10.2217/imt.14.123
|
[111]
|
Casucci, M., Hawkins, R.E., Dotti, G. and Bondanza, A. (2015) Overcoming the Toxicity Hurdles of Genetically Targeted T Cells. Cancer Immunology, Immunotherapy, 64, 123-130. https://doi.org/10.1007/s00262-014-1641-9
|
[112]
|
Kochenderfer, J.N., et al. (2015) Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated with Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor. Journal of Clinical Oncology, 33, 540-549. https://doi.org/10.1200/JCO.2014.56.2025
|
[113]
|
Riegler, L.L., Jones, G.P. and Lee, D.W. (2019) Current Approaches in the Grading and Management of Cytokine Release Syndrome after Chimeric Antigen Receptor T-Cell Therapy. Therapeutics and Clinical Risk Management, 15, 323-335.
https://doi.org/10.2147/TCRM.S150524
|
[114]
|
Maude, S.L., et al. (2018) Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. The New England Journal of Medicine, 378, 439-448. https://doi.org/10.1056/NEJMoa1709866
|
[115]
|
Schuster, S.J., et al. (2017) Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. The New England Journal of Medicine, 377, 2545–2554.
https://doi.org/10.1056/NEJMoa1708566
|
[116]
|
Neelapu, S.S., et al. (2017) Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. The New England Journal of Medicine, 377, 2531-2544. https://doi.org/10.1056/NEJMoa1707447
|
[117]
|
Lee, D.W., et al. (2019) ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation, 25, 625-638.
https://doi.org/10.1016/j.bbmt.2018.12.758
|
[118]
|
Santomasso, B.D., Bachier, C., Westin, J., Rezvani, K. and Shpall, E.J. (2022) The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. American Society of Clinical Oncology-Educational Book, 39, 433-444. https://doi.org/10.1200/EDBK_238691
|
[119]
|
Garcia Borrega, J., et al. (2019) In the Eye of the Storm: Immune-Mediated Toxicities Associated with Car-T Cell Therapy. HemaSphere, 3, e191.
https://doi.org/10.1097/HS9.0000000000000191
|
[120]
|
Andtbacka, R.H.I., et al. (2015) Talimogene Laherparepvec Improves Durable Response Rate in Patients with Advanced Melanoma. Journal of Clinical Oncology, 33, 2780-2788. https://doi.org/10.1200/JCO.2014.58.3377
|
[121]
|
Lichty, B.D., Breitbach, C.J., Stojdl, D.F. and Bell, J.C. (2014) Going Viral with Cancer Immunotherapy. Nature Reviews Cancer, 14, 559-567.
https://doi.org/10.1038/nrc3770
|
[122]
|
Rezaei, R., et al. (2021) Combination Therapy with CAR T Cells and Oncolytic Viruses: A New Era in Cancer Immunotherapy. Cancer Gene Therapy, 29, 647-660.
https://doi.org/10.1038/s41417-021-00359-9
|
[123]
|
Aalipour, A., et al. (2020) Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy. Molecular Therapy—Oncolytics, 17, 232-240.
https://doi.org/10.1016/j.omto.2020.03.018
|
[124]
|
Li, Y., et al. (2020) Oncolytic Adenovirus Targeting TGF-β Enhances Anti-Tumor Responses of Mesothelin-Targeted Chimeric Antigen Receptor T Cell Therapy against Breast Cancer. Cellular Immunology, 348, Article ID: 104041.
https://doi.org/10.1016/j.cellimm.2020.104041
|
[125]
|
Porter, C.E., et al. (2020) Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Molecular Therapy, 28, 1251-1262.
https://doi.org/10.1016/j.ymthe.2020.02.016
|
[126]
|
Park, A.K., et al. (2020) Effective Combination Immunotherapy Using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors. Science Translational Medicine, 11, eaaz1863. https://doi.org/10.1126/scitranslmed.aaz1863
http://stm.sciencemag.org/
|
[127]
|
Watanabe, K., et al. (2018) Pancreatic Cancer Therapy with Combined Mesothelin-Redirected Chimeric Antigen Receptor T Cells and Cytokine-Armed Oncolytic Adenoviruses. JCI Insight, 3, e99573. https://doi.org/10.1172/jci.insight.99573
|
[128]
|
Wing, A., et al. (2018) Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-Cell Engager. Cancer Immunology Research, 6, 605-616. https://doi.org/10.1158/2326-6066.CIR-17-0314
|
[129]
|
Moon, E.K., et al. (2018) Intra-Tumoral Delivery of CXCL11 via a Vaccinia Virus, but Not by Modified T Cells, Enhances the Efficacy of Adoptive T Cell Therapy and Vaccines. Oncoimmunology, 7, e1395997.
https://doi.org/10.1080/2162402X.2017.1395997
|
[130]
|
Shaw, A.R., et al. (2017) Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Molecular Therapy, 25, 2440-2451. https://doi.org/10.1016/j.ymthe.2017.09.010
|
[131]
|
Rosewell Shaw, A., et al. (2017) Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Molecular Therapy, 25, 2440-2451. https://doi.org/10.1016/j.ymthe.2017.09.010
|
[132]
|
Nishio, N., et al. (2014) Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor-Modified T Cells in Solid Tumors. Cancer Research, 74, 5195-5205. https://doi.org/10.1158/0008-5472.CAN-14-0697
|
[133]
|
Charrot, S., Hallam, S. and Hallam, C.S. (2019) CAR-T Cells: Future Perspectives. HemaSphere, 2, e188. https://doi.org/10.1097/HS9.0000000000000188
|
[134]
|
Turtle, C.J., Riddell, S.R. and Maloney, D.G. (2016) CD19-Targeted Chimeric Antigen Receptor-Modified T-Cell Immunotherapy for B-Cell Malignancies. Clinical Pharmacology & Therapeutics, 100, 252-258. https://doi.org/10.1002/cpt.392
|
[135]
|
Pan, J., et al. (2017) High Efficacy and Safety of Low-Dose CD19-Directed CAR-T Cell Therapy in 51 Refractory or Relapsed B Acute Lymphoblastic Leukemia Patients. Leukemia, 31, 2587-2593. https://doi.org/10.1038/leu.2017.145
|
[136]
|
Brudno, J.N., et al. (2016) Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress after Allogeneic Hematopoietic Stem-Cell Transplantation without Causing Graft-versus-Host Disease. Journal of Clinical Oncology, 34, 1112-1121.
https://doi.org/10.1200/JCO.2015.64.5929
|
[137]
|
Turtle, C.J., et al. (2017) Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated with CD19-Specific Chimeric Antigen Receptor-Modified T Cells after Failure of Ibrutinib. Journal of Clinical Oncology, 35, 3010-3020.
https://doi.org/10.1200/JCO.2017.72.8519
|
[138]
|
Turtle, C.J., Robinson, E.M., Chaney, C. and Melville, K. (2015) Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves in Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes. Blood, 126, Article No. 184.
https://doi.org/10.1182/blood.V126.23.184.184
|
[139]
|
Wang, C.M., et al. (2017) Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial. Clinical Cancer Research, 23, 1156-1166.
https://doi.org/10.1158/1078-0432.CCR-16-1365
|
[140]
|
Cohen, A.D., Garfall, A.L., Stadtmauer, E.A., Lacey, S.F., Ambrose, E. and Ferthio, R. (2016) B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study. Blood, 128, Article No. 1147.
https://doi.org/10.1182/blood.V128.22.1147.1147
|
[141]
|
Ormhoj, M., Bedoya, F., Frigault, M.J. and Maus, M.V. (2017) CARs in the Lead against Multiple Myeloma. Current Hematologic Malignancy Reports, 12, 119-125. https://doi.org/10.1007/s11899-017-0373-2
|
[142]
|
Chekmasova, A.A., et al. (2010) Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen. Clinical Cancer Research, 16, 3594-3607.
https://doi.org/10.1158/1078-0432.CCR-10-0192
|
[143]
|
Li, J., Li, W., Huang, K., Zhang, Y., Kupfer, G. and Zhao, Q. (2018) Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy for Solid Tumors: Lessons Learned and Strategies for Moving Forward. Journal of Hematology and Oncology, 11, Article No. 22. https://doi.org/10.1186/s13045-018-0568-6
|
[144]
|
Marofi, F., et al. (2021) CAR T Cells in Solid Tumors: Challenges and Opportunities. Stem Cell Research & Therapy, 12, Article No. 81.
https://doi.org/10.1186/s13287-020-02128-1
|
[145]
|
Jung, M., et al. (2020) Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. Molecular Therapy—Oncolytics, 18, 587-601.
https://doi.org/10.1016/j.omto.2020.08.009
|
[146]
|
Wei, X., et al. (2017) PSCA and MUC1 in Non-Small-Cell Lung Cancer as Targets of Chimeric Antigen Receptor T Cells. Oncoimmunology, 6, e1284722.
https://doi.org/10.1080/2162402X.2017.1284722
|
[147]
|
Transl, J., et al. (2020) 32A9, a Novel Human Antibody for Designing an Immunotoxin and CAR-T Cells against Glypican-3 in Hepatocellular Carcinoma. Journal of Translational Medicine, 18, Article No. 295.
https://doi.org/10.1186/s12967-020-02462-1
|
[148]
|
Sureban, S.M., et al. (2020) DCLK1 Monoclonal Antibody-Based CAR-T Cells as a Novel Treatment Strategy against Human Colorectal Cancers. Cancers, 12, Article No. 54.
|
[149]
|
Grada, Z., et al. (2013) TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Molecular Therapy—Nucleic Acids, 2, E105.
https://doi.org/10.1038/mtna.2013.32
|
[150]
|
Yan, W., Liu, Z., Liu, J., Xia, Y., Hu, K. and Yu, J. (2020) Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies. BioMed Research International, 2020, Article ID: 4241864.
https://doi.org/10.1155/2020/4241864
|
[151]
|
Jones, B.S., Lamb, L.S., Goldman, F. and Di Stasi, A. (2014) Improving the Safety of Cell Therapy Products by Suicide Gene Transfer. Frontiers in Pharmacology, 5, Article No. 254. https://doi.org/10.3389/fphar.2014.00254
|
[152]
|
Zhou, X., et al. (2015) Inducible Caspase-9 Suicide Gene Controls Adverse Effects from Alloreplete T Cells after Haploidentical Stem Cell Transplantation. Blood, 125, 4103-4113. https://doi.org/10.1182/blood-2015-02-628354
|